Beijing Beilu Pharmaceutical Co., Ltd. (300016.SZ) is a China-based pharmaceutical company principally engaged in the research, development, production and sales of chemical drugs, with a leading position in contrast media. Founded in 1992 and headquartered in Beijing at No.32 Xizhimen North Street, Haidian District, the company offers a comprehensive portfolio of products including MRI gadolinium-based contrast media such as gadobutrol injection and gadopentetate dimeglumine injection; CT/X-ray iodine-containing contrast media such as iopamidol injection, iodixanol injection and iomeprol injection; central nervous system drugs including Jiuweizhenxin Granules for generalized anxiety disorder and insomnia; and endocrinology products such as glimepiride tablets and repaglinide tablets for type 2 diabetes treatment. Beilu operates production sites in Beijing's Miyun District and Hebei's Cangzhou, with geographic reach spanning China and exports to Southeast Asia, Africa, Latin America and the Middle East. In recent developments, the company completed the acquisition of Zhejiang Hichi Pharmaceutical Co., Ltd. in 2020 to secure API supply for iodine contrast agents and enhance industrial chain integration; established Luzhibao Pharmaceutical Co., Ltd. in Bozhou, Anhui in 2023 to bolster traditional Chinese medicine capabilities, holding 59 related approvals; and signed a strategic cooperation agreement with Anhui Chengqingtang Traditional Chinese Medicine Co., Ltd. in early 2025 to develop classic TCM formulations.